Connect Biopharma Holdings Ltd 8-K

What Happened
Connect Biopharma Holdings Ltd (CNTB) filed an 8-K disclosing that Kan Chen, Ph.D., a partner at Qiming Venture Partners, resigned from the company's Board of Directors and from the Nominating and Corporate Governance Committee, effective December 17, 2025. The company said Dr. Chen’s resignation is not due to any disagreement with the company’s operations, policies or practices.

Key Details

• Dr. Kan Chen resigned from the Board and the Nominating and Corporate Governance Committee effective December 17, 2025.
• Dr. Chen is a partner at Qiming Venture Partners and cited the company’s strategic shift to a more U.S.-centric organization — including U.S.-based management and development in the U.S. and Europe — as the reason he felt it was an appropriate time to step down.
• The 8-K was filed December 23, 2025 and signed by President David Szekeres.
• The filing notes explicitly that the resignation was not due to any disagreement with the company.

Why It Matters
Board changes can affect corporate governance and investor perceptions. This resignation reduces representation from a Qiming partner on the board and reflects the company’s stated strategic move toward U.S.-centric management and development. Management has characterized the departure as voluntary and not based on any dispute with the company; the filing does not name a replacement or describe additional board changes. Investors should note the governance shift and monitor future filings for any director appointments or committee reassignments.